Gene therapy maker bluebird to revise financials after accounting errors

The restatement will have no impact on its revenue or current cash position, said a spokesperson for the company, which has contract manufacturing agreements with Thermo Fisher Scientific and Lonza, among others, according to bluebird's annual report released last year.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/X1OdWH6
via